Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Tesla Weighs China Business Separation Amid SpaceX Merger Speculation 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
INDIANAPOLIS and SAN FRANCISCO, April 10, 2018 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that it plans to host a conference call and live audio webcast on Thursday, April 12, 2018, at 8:00 am ET/2:00 pm CET to review interim results from Phase 1a and 1b studies of ABI-H0731 being featured in a “late-breaker” poster presentation at The International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at assemblybio.com. Alternatively, participants may dial (866) 362-6480 (domestic) or (706) 679-0386 (international) and refer to conference ID 3669097.
The archived webcast will be available on Assembly’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly’s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit assemblybio.com.
Contacts
Assembly Biosciences, Inc.
Investors:
Lauren Glaser
(415) 521-3828
[email protected]
